700 Technology Square, 3rd Floor
About ImaraImara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
Founder and CEO: James McArthur
Please click here for clinical trial information.
19 articles with Imara
Imara Inc. announced that the company will deliver an oral presentation on IMR-687 at the 24th Congress of the European Hematology Association being held from June 13 – 16, 2019, in Amsterdam.
Imara, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to IMR-687, the company’s lead product candidate for the treatment of sickle cell disease.
Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced it has appointed Michael P. Gray as Chief Financial and Chief Operating Officer
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced it has hired Willem H. Scheele, M.D., as Chief Medical Officer.
Proceeds to Advance IMR-687 for the Treatment of Sickle Cell Disease (SCD) and Thalassemia, and Expand Company Pipeline
Imara Inc. today announced it presented an update on its sickle cell disease program at the Annual Sickle Cell and Thalassaemia Conference (ASCAT) held this week, October 22-24 at the Westminster Bridge, County Hall in London.
Imara Announces Upcoming Presentation at the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention
Imara today announced it will provide an update on its sickle cell disease program at the Sickle Cell Disease Association of America’s (SCDAA) 46th Annual National Convention.
Imara Announces CEO Rahul Ballal, Ph.D., Will Present at the 7th Annual Sickle Cell Disease Therapeutic Conference
Interim Data from Ongoing Phase 2a Clinical Trial of IMR-687 Expected in the Fourth Quarter
8/20/2018This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.
Imara Announces Appointment of Kevin B. Johnson, Ph.D., MBA, as Senior Vice President of Regulatory and Quality
Dr. Johnson brings more than 25 years of experience guiding the regulatory and product development strategies for biotechnology and pharmaceutical companies in all stages of development and across a range of therapeutic areas.
James McArthur, Ph.D., joins board of directors as company expansion accelerates.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
Imara Inc. today announced additions to its clinical development team with the appointments of Joe Datt, M.D., as Senior Vice President, Clinical Development, and Siddharth Parulkar as Head, Global Clinical Operations.
IMR-687 is designed as an oral therapy for once-daily dosing to address both the underlying red and white blood cell pathologies associated with SCD.
Imara Receives Rare Pediatric Disease Designation From FDA For Lead Product Candidate IMR-687 For Sickle Cell Disease
Imara Presents Results For IMR-687, A PDE9 Inhibitor, In Sickle Cell Disease At American Society of Hematology